Determination of myeloperoxidase in EDTA plasma: comparison of an enzyme-linked immunosorbent assay with a chemiluminescent automated immunoassay.
BACKGROUND
The increased demand in clinical chemistry laboratories for determination of myeloperoxidase (MPO) as a potential marker for cardiovascular diseases has led to the development of several analytical methods, especially enzyme-linked immunosorbent assay (ELISA, e. g. from Immundiagnostik AG), and recently a new chemiluminescent automated immunoassay (CMIA, Architect MPO assay, Abbott Diagnostics).


METHODS
We compared data from 115 patients obtained from an ELISA reference method (Immundiagnostik AG) with data obtained from the automated Architect MPO assay.


RESULTS
The new MPO assay from Abbott Diagnostics correlates well with the ELISA (y=0.767x+7.035; R(2)=0.9204). The difference plot according to Bland-Altman analysis shows a mean bias of -1.048 microg/l, with a probability of 95%.


CONCLUSIONS
The Architect MPO assay can easily be adapted to the Architect instrument system and it is advantageous as far as technology and analysis time are concerned. This new automated MPO assay shows excellent analytical performance and provides a precise and convenient automated method for the measurement of MPO.
Zelzer
Sieglinde
S
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria. sieglinde.zelzer@klinikum-graz.at
Khoschsorur
Gholamali
G
Stettin
Mariana
M
Weihrauch
Gisela
G
Truschnig-Wilders
Martini
M
D001331:Automation; D004492:Edetic Acid; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D049449:Luminescence; D009195:Peroxidase / Q000097:blood*; D014180:Transplantation
D004492:Edetic Acid; D009195:Peroxidase